Article Trunk



Posts Tagged ‘GSK-3β Inhibitors Therapeutics drug development’

Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors Therapeutics Pipeline Analysis 2019

06.07.2019 · Posted in Health Care Articles

Glycogen synthase kinase 3 beta (GSK-3β) is an attractive target for the treatment of psychiatric disorders and neurodegenerative diseases. Many GSK-3β inhibitors have been developed for the treatment of different central nervous system disorders. But, for an effective therapy, high IC50 values should be avoided and ATP-competition should be reduced during enzyme-compound binding. Studies suggested ...